Literature DB >> 27876604

Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group.

Meredith E Giuliani1, Andrew Hope2, Victor Mangona3, Matthias Guckenberger4, Frederick Mantel5, Heike Peulen6, Jan-Jakob Sonke6, José Belderbos6, Maria Werner-Wasik7, Hong Ye3, Inga S Grills3.   

Abstract

INTRODUCTION: The objective of this study was to determine the predictors and patterns of regional recurrence (RR) following stereotactic body radiotherapy (SBRT) for primary lung cancers.
MATERIAL AND METHODS: Details of patient factors, treatment, and outcome factors were extracted from a multi-institutional (5) database. All events were calculated from the end of radiotherapy. Estimates of local recurrence, RR, and distant metastases (DM) were calculated using the competing risk method. Cause-specific and overall survival were calculated using the Kaplan-Meier method. Details of locations and number of simultaneous RRs were categorized by lymph node anatomic station.
RESULTS: A total of 734 patients were analyzed. The median follow-up was 3.0 years in surviving patients. Four hundred seventy-six (65%) patients had pathologic proof of disease. There were 64 patients with RR. The 2-year local recurrence, RR, and distant metastases rates were 5.6%, 9.0%, and 14.6% respectively. The 2-year cause-specific and overall survival were 89.9% and 63.7%, respectively. There were 136 simultaneous sites of RR. There were 21 recurrences in stations 4R (15.4%), 9 (6.6%) in 4L, 30 (22%) in 7, 19 (13.9%) in 10R, and 14 (10.3%) in 10L. The most common stations for isolated recurrence (n = 19) were station 7 (n = 5; 26.3%) and station 10R (n = 6; 31.6%). The most common RR levels were stations 4 and 7 for right and left upper lobe, stations 5, 7, and 10 for left lower lobe tumors, and stations 7 and 10 for right lower lobe tumors.
CONCLUSION: Stations 4, 7, and 10 were the most common stations for RR. These patterns of recurrence may guide nodal staging procedures prior to SBRT.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EBUS; Patterns of failure; SABR; Staging; Stereotactic body radiotherapy

Mesh:

Year:  2016        PMID: 27876604     DOI: 10.1016/j.cllc.2016.10.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  11 in total

1.  Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.

Authors:  Alberto Cerra-Franco; Sheng Liu; Michella Azar; Kevin Shiue; Samantha Freije; Jason Hinton; Christopher R Deig; Donna Edwards; Neil C Estabrook; Susannah G Ellsworth; Ke Huang; Khalil Diab; Mark P Langer; Richard Zellars; Feng-Ming Kong; Jun Wan; Tim Lautenschlaeger
Journal:  Clin Lung Cancer       Date:  2018-12-29       Impact factor: 4.785

2.  Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy.

Authors:  Madison R Kocher; Anand Sharma; Elizabeth Garrett-Mayer; James G Ravenel
Journal:  J Comput Assist Tomogr       Date:  2018 Jan/Feb       Impact factor: 1.826

3.  Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.

Authors:  Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2017-09-05       Impact factor: 3.621

4.  Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study.

Authors:  Moonkyoo Kong; Ji-Youn Sung; Seung Hyeun Lee
Journal:  Onco Targets Ther       Date:  2020-08-18       Impact factor: 4.147

5.  Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer.

Authors:  Masaki Nakamura; Ryo Nishikawa; Hiroshi Mayahara; Haruka Uezono; Aya Harada; Naoki Hashimoto; Hideki Nishimura
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

6.  Incidence and clinical relevance of non-small cell lung cancer lymph node micro-metastasis detected by staging endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Adam R Belanger; Johnathan Hollyfield; Gabriella Yacovone; Agathe S Ceppe; Jason A Akulian; A Cole Burks; M Patricia Rivera; Leslie G Dodd; Jason M Long; Benjamin E Haithcock; Chad V Pecot
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

7.  Target volume definition for staple line recurrences of non-small cell lung cancer.

Authors:  Jan Nuzhat; Nitai D Mukhopadhyay; Elisabeth Weiss
Journal:  Rep Pract Oncol Radiother       Date:  2021-12-30

8.  Prognostic factors and clinical outcomes after stereotactic radiotherapy for primary lung tumors.

Authors:  Isabel Rodrigues; Tiago Figueiredo; João Gagean; Carolina Ferreira; André Laranja; Tiago Ramos; Sofia Conde; Diana Moreira; Joana Cardia
Journal:  Rep Pract Oncol Radiother       Date:  2020-10-03

Review 9.  Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review.

Authors:  Haruo Matsushita; Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Katagiri; Noriyuki Kadoya
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 10.  Difference in Acquired Radioresistance Induction Between Repeated Photon and Particle Irradiation.

Authors:  Katsutoshi Sato; Takashi Shimokawa; Takashi Imai
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.